Geron Ord Shs (GERN)

$2.06 0.02 (0.98%)

14:06 EDT GERN Stock Quote Delayed 30 Minutes

Volume:

Previous Close $2.04

Market Cap 356.55M

PE Ratio -12.12

EPS -0.17

Volume (Avg. Vol.) 1.10M

Day's Range 1.99 - 2.06

52-Week Range 0.75 - 2.40

Dividend & Yield N/A (N/A)

GERN Stock Predictions, Articles, and Geron Ord Shs News

From InvestorPlace
From the Web

7 Penny Stocks To Buy with Massive Upside Potential

By Maya Sasson, Writer, TipRanks Apr 8, 2020

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

7 Healthcare Stocks With 100% Street Support

By Maya Sasson, Writer, TipRanks Jan 22, 2020

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

5 Top Stock Trades for Friday — BBBY, RAD and NFLX

By Bret Kenwell, InvestorPlace Contributor Sep 27, 2018

Geron plunged almost 70% and Bed Bath & Beyond dropped more than 20%. Here are our top stock trades for Friday.

7 Biotech Stocks to Buy Now

By Chris Lau, InvestorPlace Contributor Sep 19, 2018

Biotech companies are recovering nicely this year. With a quarter left to go, the upside potential is high for those biotech stocks that dipped recently.

Geron Corporation Stock Shoots Up on Job Posting News

By Karl Utermohlen, InvestorPlace Writer Aug 24, 2018

Geron Corporation (GERN) stock went gangbusters on Friday as partner Johnson & Johnson (JNJ) opened a new job position for an EMEA Strategic Pricing Manager.

8 Undervalued Biotech Stocks to Watch

By Josh Enomoto, InvestorPlace Contributor Aug 20, 2018

Volatility across all categories of biotech stocks makes this present juncture an ideal time to consider picking up undervalued names.

Compare Brokers

5 Risky, But Rewarding, Ways to Play the Rebound

By Anthony Mirhaydari, InvestorPlace Market Strategist Feb 7, 2018

These stocks and ETFs to buy have a good chance to give investors handsome rewards; however, they are not without significant risk.

24 Biotechnology Stocks to Sell Now

By Portfolio Grader Nov 28, 2016

This week, the ratings of 24 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Gilead Sciences, Inc. (GILD) Stock Falters on Q3 Earnings Miss

By Zacks Investment Research Nov 2, 2016

Gilead Sciences (GILD) struggled in its third quarter thanks to lower Hepatitis C treatment sales. GILD stock is being punished as a result.

23 Biotechnology Stocks to Sell Now

By Portfolio Grader Sep 26, 2016

This week, the overall grades of 23 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").